The stock of Spark Therapeutics Inc (NASDAQ:ONCE) is a huge mover today! About 170,849 shares traded hands. Spark Therapeutics Inc (NASDAQ:ONCE) has risen 97.25% since March 8, 2016 and is uptrending. It has outperformed by 87.94% the S&P500.
The move comes after 5 months negative chart setup for the $1.88 billion company. It was reported on Oct, 11 by Barchart.com. We have $55.46 PT which if reached, will make NASDAQ:ONCE worth $131.60 million less.
Analysts await Spark Therapeutics Inc (NASDAQ:ONCE) to report earnings on November, 2. They expect $-0.98 EPS, down 40.00% or $0.28 from last year’s $-0.7 per share. After $-1.04 actual EPS reported by Spark Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.77% EPS growth.
Spark Therapeutics Inc (NASDAQ:ONCE) Ratings Coverage
Out of 10 analysts covering Spark Therapeutics (NASDAQ:ONCE), 5 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 50% are positive. Spark Therapeutics has been the topic of 12 analyst reports since August 21, 2015 according to StockzIntelligence Inc. The company was initiated on Friday, June 3 by Cantor Fitzgerald. The stock has “Hold” rating given by Wunderlich on Thursday, December 24. The firm earned “Neutral” rating on Wednesday, December 23 by Chardan Capital Markets. Stifel Nicolaus initiated Spark Therapeutics Inc (NASDAQ:ONCE) on Friday, September 2 with “Buy” rating. The rating was downgraded by Zacks to “Hold” on Friday, August 21. TH Capital maintained Spark Therapeutics Inc (NASDAQ:ONCE) rating on Monday, October 5. TH Capital has “Buy” rating and $90 price target. Zacks downgraded the shares of ONCE in a report on Wednesday, September 2 to “Sell” rating. The rating was initiated by Evercore with “Buy” on Tuesday, April 12. On Wednesday, March 30 the stock rating was initiated by Goldman Sachs with “Neutral”. As per Monday, October 5, the company rating was maintained by Roth Capital.
According to Zacks Investment Research, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania.”
Insitutional Activity: The institutional sentiment decreased to 2.11 in 2016 Q2. Its down 0.03, from 2.14 in 2016Q1. The ratio dived, as 18 funds sold all Spark Therapeutics Inc shares owned while 18 reduced positions. 28 funds bought stakes while 48 increased positions. They now own 23.88 million shares or 24.93% more from 19.12 million shares in 2016Q1.
Morgan Stanley accumulated 26,515 shares or 0% of the stock. Emerald Advisers Pa last reported 0.09% of its portfolio in the stock. Alps Advsrs accumulated 38,489 shares or 0.02% of the stock. Thompson Davis reported 1,000 shares or 0.08% of all its holdings. Neuberger Berman Gru Ltd Liability Co has 9,000 shares for 0% of their US portfolio. Cam Gp Hldgs A S accumulated 67,400 shares or 0.07% of the stock. Bailard has 0.25% invested in the company for 40,600 shares. Deerfield has invested 0.74% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE). Us National Bank De accumulated 0% or 100 shares. Voloridge Mngmt Limited accumulated 97,654 shares or 0.14% of the stock. Clearbridge Investments Ltd Llc holds 641,962 shares or 0.04% of its portfolio. Axa has 0.03% invested in the company for 140,278 shares. Alliancebernstein Limited Partnership last reported 0% of its portfolio in the stock. Fmr Ltd Com accumulated 4.50 million shares or 0.03% of the stock. Tocqueville Asset Mngmt L P last reported 50,650 shares in the company.
More notable recent Spark Therapeutics Inc (NASDAQ:ONCE) news were published by: Philly.com which released: “Spark Therapeutics releases gene-therapy data” on August 10, 2016, also Fool.com with their article: “Why Spark Therapeutics Caught Fire and Rallied Higher Today” published on May 19, 2016, Globenewswire.com published: “Spark Therapeutics, Inc. to Host Conference Call on August 10th at 8:30a.m. to …” on August 02, 2016. More interesting news about Spark Therapeutics Inc (NASDAQ:ONCE) were released by: Philly.com and their article: “Spark Therapeutics buys Dublin gene-therapy company” published on March 07, 2016 as well as Globenewswire.com‘s news article titled: “Spark Therapeutics, Inc. to Host Conference Call on Monday June 13th at 8:30 a …” with publication date: June 09, 2016.
ONCE Company Profile
Spark Therapeutics, Inc. (Spark), incorporated on March 13, 2013, is engaged in developing products in the field of gene therapy. The Firm focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. The Company’s SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). The Company’s product candidates include SPK-CHM and SPK-FIX. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. The Firm is also conducting preclinical studies on a product candidate for the treatment of Huntington’s disease, a hereditary genetic disorder.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.